Company intelligence / Profile preview
Akero Therapeutics
South San Francisco, California, United Statesakerotx.com ↗
- Ownership
- Public · AKRO
- Employees
- ~63
- Development stage
- Phase 3
01
Overview
Efruxifermin has demonstrated statistically significant reversal of cirrhosis after prolonged treatment in Phase 2b studies; improvements in fibrosis stages without worsening MASH; safety and tolerability when combined with GLP1 therapies; resolution of MASH; reduction in liver injury markers; improved insulin sensitivity; favorable lipoprotein changes linked to cardiovascular risk reduction[3][6][7]. The drug is currently being evaluated in three ongoing Phase III trials including SYNCHRONY Histology and Real World studies with data expected by mid/late 2026[6].
- Therapeutic areas
- GastroenterologyMetabolic Disorders
- Modalities
- Engineered protein therapeuticsFc-FGF21 fusion protein analogsProtein biologic modality
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
License agreement with Amgen for development/manufacture/sale rights for efruxifermin[2][4]
04
Financials
- Market cap
- $4.5B
- Total revenue
- $0
- Enterprise value
- $3.8B
Beyond the preview
Go deeper on Akero Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akero Therapeutics.